Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie Inc. (ABBV) shares traded near their all-time high Friday as the pharmaceutical company posted better-than-expected results and raised its sales forecast for two of its key medicines.

AbbVie Boosts Outlook for Two Key Drugs After Beating Profit, Sales Estimates

AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.

AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs

AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript

Drugmakers Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) and Abbvie Inc (NYSE:ABBV) on Friday both reported better than expected financial results for the December quarter, sending shares of both stocks higher.  For 4Q, Bristol Meyers Squibb reported adjusted earnings per share (EPS) of $1.70 on revenue of $11.48 billion, surpassing Wall Street estimates of $1.52 and $11.08 billion respectively.

Bristol Meyers Squibb, AbbVie top 4Q sales and profit estimates

The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AbbVie (ABBV) Reports Q4 Earnings: What Key Metrics Have to Say

AbbVie NYSE: ABBV is turning an important corner in 2024 and is on track to resume growth. Its Humira-related patent cliff aside, the business is stronger than ever, and the patent cliff is more of a bump than a steep drop.

AbbVie turns a corner; patent cliff fears were overblown

Eli Lilly

Novo Nordisk

Novartis

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.

4 Large Drug Stocks Trying to Survive the Industry Challenges

AbbVie (ABBV) came out with quarterly earnings of $2.79 per share, beating the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $3.60 per share a year ago.

AbbVie (ABBV) Q4 Earnings and Revenues Top Estimates

AbbVie raised its long-term guidance for Skyrizi and Rinvoq, two key immunology drugs, on Friday. AbbVie stock inched higher.

AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira.

AbbVie raises its fiscal 2027 sales expectations for Skyrizi and Rinvoq.

AbbVie Posts Revenue Beat as Humira Sales Tumble. Other Immunology Drugs Are Selling.

Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q4 and full year financial results for 2023 this afternoon. The American medical R&D powerhouse had some setbacks in the year, including disappointing profits from their drug Humira, which lost significant market share to generic knockoffs in both the US and abroad in 2023.

AbbVie posts less-than-healthy financial results for 2023

AbbVie Inc beat Wall Street estimates for fourth-quarter profit on Friday, helped by a smaller-than-expected decline in sales of its blockbuster drug, Humira, and strong demand for Botox amid stiff competition.

AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals

AbbVie Inc. ABBV, +1.94% on Friday reported fourth-quarter sales that topped analysts' estimates, even as it faces low-cost competition for its top-selling drug, Humira.

AbbVie's fourth-quarter sales top estimates despite plunging Humira revenues

Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to 2023 Acquired IPR&D and Milestones Expense. Delivers Full-Year Net Revenues of $54.318 Billion, a Decrease of 6.4 Percent on a Reported Basis and 5.9 Percent on an Operational Basis.

AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results

Jazz Pharmaceuticals

There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024

-- New report incorporates in-depth interviews, industry research and social listening to understand the role of individuality in the world of aesthetics -- -- Report underpins ongoing commitment to aesthetics accessibility and inclusivity to achieve desired patient outcomes -- IRVINE, Calif. , Jan. 31, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie (NYSE: ABBV) company and a global leader in medical aesthetics treatments, released the "Decoding the Future of Aesthetic Individuality" report, which aims to deepen the understanding of the evolving consumer mix and their aesthetic needs.

Allergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-Expression

Evaluate the expected performance of AbbVie (ABBV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Unveiling AbbVie (ABBV) Q4 Outlook: Wall Street Estimates for Key Metrics

Dollar Tree

Hershey

We see daily analyst upgrades and downgrades, coming with price targets. They can be helpful tools for investors, providing a more structured plan and helping to inject positivity surrounding future performance.

3 Stocks Enjoying Favorable Analyst Coverage

The latest trading day saw AbbVie (ABBV) settling at $163.91, representing a -0.3% change from its previous close.

AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

Amgen

Bristol-Myers

Johnson & Johnson

Merck

Pfizer

Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's first ever price negotiations.

Pharma industry to get US government price cut proposals by Thursday

Medtronic

Medtronic's global medical device business has supported annual dividend raises since 1978, and it's well positioned for more growth. AbbVie's lead drug fell off a patent cliff last year, but soaring sales of recently launched treatments make the stock a buy right now.

2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now

NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE

Healthcare had a mediocre performance in 2023, but it remains a suitable addition to a diversified portfolio due to its defensive characteristics. AbbVie Inc. and Merck & Co., Inc. are attractive healthcare players that also provide steady dividends and potential for growth. AbbVie is navigating the Humira patent cliff and expects to return to earnings growth in 2025, while Merck's Keytruda is driving sales but faces competition with a patent expiration in 2028.

AbbVie And Merck: Defensive Healthcare Plays Providing Income

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline

A key component of income investing is a portfolio that includes safe dividends, those that are unlikely to shrink or disappear.

News for AbbVie Stock (ABBV)